Novobiocin Sodium
Cat. No.：YN251038
| 产品名称: | Novobiocin Sodium |
| CAS No.: | 1476-53-5 |
| Chemical Name: | N-[7-[[3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-α-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-benzamide, monosodium salt |
| Synonyms: | Albamycin; Cathomycin |
| 分子量: | 634.61 |
| 分子式: | C₃₁H₃₅N₂NaO₁₁ |
| SMILES: | CC1=C(OC2=O)C(C(O)=C2NC(C3=CC(C/C=C(C)/C)=C(O[Na])C=C3)=O)=CC=C1O[C@H](OC(C)(C)[C@H](OC)[C@H]4OC(N)=O)[C@@H]4O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Novobiocin Sodium (Albamycin; Cathomycin) 是一种口服抗生素 (antibiotic) 化合物，源于链霉菌，也是一个强效的DNA gyrase抑制剂通过结合 ATP 结合位点在 ATP 酶亚基。Novobiocin Sodium 对革兰氏阳性菌有较强的抗菌活性，但由于外膜中含有脂多糖，对革兰氏阴性菌的抗菌活性有限。Novobiocin Sodium 与Hsp90的 c 端结合，轻微诱导 Hsp90 依赖的 client 蛋白的降解 (IC50=700 μM)。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Collin, F., Karkare, S., and Maxwell, A.Exploiting bacterial DNA gyrase as a drug target: Current state and perspectivesAppl. Microbiol. Biotechnol.92(3),479-497(2011)
Lockshon, D., and Morris, D.R.Positively supercoiled plasmid DNA is produced by treatment of Escherichia coli with DNA gyrase inhibitorsNucleic Acids Res.11(10),2999-3017(1983)
Allan, R.K., Mok, D., Ward, B.K., et al.Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: Evidence that coumarin antibiotics disrupt Hsp90 dimerizationJ. Biol. Chem.281(11),7161-7171(2006)
Hall, J.A., Seedarala, S., Zhao, H., et al.Novobiocin Analogues That Inhibit the MAPK PathwayJ. Med. Chem.59(3),925-933(2016)
